Core Viewpoint - The stock of 旺山旺水-B (02630) surged over 15% in the afternoon, reaching a price of 88 HKD, with a trading volume of 13.33 million HKD, following the announcement of a licensing agreement with 先声药业 for the new indication of VV116 [1] Group 1: Licensing Agreement - 旺山旺水 has entered into a licensing agreement with 先声药业, granting the latter exclusive rights to the use of hydrogen bromide dextromethorphan suspension for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections in the Greater China region [1] - This collaboration aims to leverage the strengths of both companies in research, production, and commercialization to accelerate the clinical development and commercialization of VV116, ultimately benefiting more patients [1] Group 2: Company Pipeline and Focus Areas - 旺山旺水 is focused on three main therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - As of October 21, 2025, the company has established a diversified pipeline of nine innovative products, with two in the commercialization stage, four in clinical stages, and three in preclinical stages [1] - In addition to its innovative drug pipeline, 旺山旺水 is also involved in the generic drug sector, with three products either commercialized or nearing commercialization [1] - The company's two core products are LV232 and TPN171 [1]
旺山旺水-B午后拉升逾15% 近期与先声药业就VV116新适应症订立许可协议